Magnetic sphincter augmentation (MSA) of the gastroesophageal junction with the @entity6149 Reflux Management System is an alternative to fundoplication for @entity354 ( @entity354 ) that was approved by the U.S. Food and Drug Administration (FDA) in March 2012. This is a prospective observational study of all @entity1 who underwent placement of the @entity6149 at two institutions from April 2012 to December 2013 to evaluate our clinical experience with the @entity6149 device after FDA approval. There were no intraoperative complications and only four mild postoperative morbidities: three urinary retentions and one readmission for dehydration. The mean operative time was 60 minutes (range, 31 to 159 minutes) and mean length of stay was 11 hours (range, 5 to 35 hours). @entity354 health-related quality-of-life scores were available for 83 per cent of @entity1 with a median follow-up of five months (range, 3 to 14 months) and a median score of four (range, 0 to 26). A total of 76.9 per cent of @entity1 were no longer taking proton pump inhibitors. The most common postoperative complaint was @entity1282 , which resolved in 79.1 per cent of @entity1 with a median time to resolution of eight weeks. There were eight @entity1 with persistent @entity1282 that required @entity384 with improvement in symptoms. MSA with @entity6149 is a safe and effective alternative to fundoplication for treatment of @entity354 . The most common postoperative complaint is mild to moderate @entity1282 , which usually resolves within 12 weeks.

Magnetic Sphincter Augmentation with the @entity6149 Device for XXXX after U.S. Food and Drug Administration Approval.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity384 :: ('MESH:D002311', 'Disease') :: ['balloon dilation'] @entity6149 :: ('57611', 'Gene') :: ['LINX'] @entity354 :: ('MESH:D005764', 'Disease') :: ['gastroesophageal reflux disease', 'GERD'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']
@entity354 :: (MESH:D005764,Disease) :: ['Gastroesophageal Reflux Disease']
